Bioarctic Ab (publ) Stock Earnings Reports

BioArctic reported a strong start to 2026, driven largely by continued global uptake of Leqembi (lecanemab). Eisai's fiscal 2025 Leqembi sales exceeded EUR 500 million, triggering a EUR 20 million commercial milestone to BioArctic and supporting growing quarterly royalty income. Management expects continued momentum from wider use of blood-based biomarkers and the roll-out of subcutaneous formulations (Iqlik) with key regulatory readouts through 2026 (U.S. PDUFA 24 Aug for subcutaneous induction; Japan Q3; China early next year). The company's R&D portfolio is advancing on two platforms — selective anti-aggregation antibodies (notably alpha-synuclein programs exidavnemab and BAN2238) and the BrainTransporter platform for improved brain delivery across multiple modalities. The Phase IIa EXIST study for exidavnemab is fully recruited (26 PD patients across two dose cohorts and 12 MSA patients at the higher dose) with top-line results expected later this year. BAN2238 is in IND-enabling activities and demonstrates preclinical signs of enhanced brain exposure without common transferrin receptor-related safety issues. Financially, Q1 royalties rose materially (quarterly royalty SEK 161m) with Q1 net revenues of SEK 438m; BioArctic reported operating profit and expects to be profitable for the full year 2026. Cash position is strong (over SEK 2 billion), enabling continued investment and potential dividends (AGM proposal SEK 2 per share). Management guided that 2026 operating costs will rise versus 2025 and revised prior guidance to expect roughly a 40%–60% increase in costs for 2026 (driven by IND-enabling and manufacturing/CMC spend), noting costs will be lumpy through the year. Key upcoming catalysts: exidavnemab Phase IIa readout later this year, regulatory decisions on Iqlik, further Leqembi data presentations at AAIC, and potential new partnership disclosures.